212 related articles for article (PubMed ID: 15828834)
21. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design.
Gabelli SB; McLellan JS; Montalvetti A; Oldfield E; Docampo R; Amzel LM
Proteins; 2006 Jan; 62(1):80-8. PubMed ID: 16288456
[TBL] [Abstract][Full Text] [Related]
22. Engineered gene over-expression as a method of drug target identification.
Sugden CJ; Roper JR; Williams JG
Biochem Biophys Res Commun; 2005 Aug; 334(2):555-60. PubMed ID: 16005849
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
Szabo CM; Matsumura Y; Fukura S; Martin MB; Sanders JM; Sengupta S; Cieslak JA; Loftus TC; Lea CR; Lee HJ; Koohang A; Coates RM; Sagami H; Oldfield E
J Med Chem; 2002 May; 45(11):2185-96. PubMed ID: 12014956
[TBL] [Abstract][Full Text] [Related]
24. Disruption of insect isoprenoid biosynthesis with pyridinium bisphosphonates.
Sen SE; Wood L; Jacob R; Xhambazi A; Pease B; Jones A; Horsfield T; Lin A; Cusson M
Insect Biochem Mol Biol; 2015 Aug; 63():113-23. PubMed ID: 26073627
[TBL] [Abstract][Full Text] [Related]
25. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
26. In Vitro and In Vivo Investigation of the Inhibition of Trypanosoma brucei Cell Growth by Lipophilic Bisphosphonates.
Yang G; Zhu W; Kim K; Byun SY; Choi G; Wang K; Cha JS; Cho HS; Oldfield E; No JH
Antimicrob Agents Chemother; 2015 Dec; 59(12):7530-9. PubMed ID: 26392508
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.
Hudock MP; Sanz-Rodríguez CE; Song Y; Chan JM; Zhang Y; Odeh S; Kosztowski T; Leon-Rossell A; Concepción JL; Yardley V; Croft SL; Urbina JA; Oldfield E
J Med Chem; 2006 Jan; 49(1):215-23. PubMed ID: 16392806
[TBL] [Abstract][Full Text] [Related]
28. Structural and thermodynamic basis of the inhibition of Leishmania major farnesyl diphosphate synthase by nitrogen-containing bisphosphonates.
Aripirala S; Gonzalez-Pacanowska D; Oldfield E; Kaiser M; Amzel LM; Gabelli SB
Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):802-10. PubMed ID: 24598749
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms of action of bisphosphonates: current status.
Roelofs AJ; Thompson K; Gordon S; Rogers MJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of a series of aromatic bisphosphonates.
Barney RJ; Wasko BM; Dudakovic A; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2010 Oct; 18(20):7212-20. PubMed ID: 20832326
[TBL] [Abstract][Full Text] [Related]
31. Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators.
Zhang Y; Cao R; Yin F; Lin FY; Wang H; Krysiak K; No JH; Mukkamala D; Houlihan K; Li J; Morita CT; Oldfield E
Angew Chem Int Ed Engl; 2010 Feb; 49(6):1136-8. PubMed ID: 20039246
[No Abstract] [Full Text] [Related]
32. Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi.
Szajnman SH; Bailey BN; Docampo R; Rodriguez JB
Bioorg Med Chem Lett; 2001 Mar; 11(6):789-92. PubMed ID: 11277521
[TBL] [Abstract][Full Text] [Related]
33. [Inhibition of bone resorption by bisphosphonates, heterogeneous group of drugs with different intracellular model of action].
Stajszczyk M
Pol Arch Med Wewn; 2001 Jul; 106(1):617-29. PubMed ID: 11928574
[No Abstract] [Full Text] [Related]
34. Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates.
Cheng F; Oldfield E
J Med Chem; 2004 Oct; 47(21):5149-58. PubMed ID: 15456258
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
Szajnman SH; Montalvetti A; Wang Y; Docampo R; Rodriguez JB
Bioorg Med Chem Lett; 2003 Oct; 13(19):3231-5. PubMed ID: 12951099
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents.
Singh US; Shankar R; Kumar A; Trivedi R; Chattopadhyay N; Shakya N; Palne S; Gupta S; Hajela K
Bioorg Med Chem; 2008 Sep; 16(18):8482-91. PubMed ID: 18752963
[TBL] [Abstract][Full Text] [Related]
37. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.
Wiemer AJ; Yu JS; Shull LW; Barney RJ; Wasko BM; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Apr; 16(7):3652-60. PubMed ID: 18308574
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.
Marma MS; Xia Z; Stewart C; Coxon F; Dunford JE; Baron R; Kashemirov BA; Ebetino FH; Triffitt JT; Russell RG; McKenna CE
J Med Chem; 2007 Nov; 50(24):5967-75. PubMed ID: 17975902
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Dunford JE; Kwaasi AA; Rogers MJ; Barnett BL; Ebetino FH; Russell RG; Oppermann U; Kavanagh KL
J Med Chem; 2008 Apr; 51(7):2187-95. PubMed ID: 18327899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
